Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A4 | Q9H015 | 1/20 | 0.55 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14330476 | 0.81 | SLC22A4 (0.54) | SLC22A4KDM3BKMT2ATDP1 | |
| SCHEMBL1867162 | 0.72 | SLC22A4 (0.51) | SLC22A4KDM3BKMT2ATDP1 | |
| SCHEMBL20925250 | 0.70 | SLC22A4 (0.72) | SLC22A4KDM3BKMT2ATDP1 | |
| SCHEMBL20925187 | 0.69 | SLC22A4 (0.70) | SLC22A4KDM3BKMT2ATDP1 | |
| SCHEMBL14279284 | 0.67 | ALDH1A1 (0.58) | KMT2A | |
| SCHEMBL10806987 | 0.63 | KDM3B (0.40) | SLC22A4KDM3BKMT2ATDP1 | |
| SCHEMBL9293068 | 0.62 | ESR1 (0.48) | — | |
| SCHEMBL9294568 | 0.62 | HPGD (0.36) | KMT2A | |
| SCHEMBL6865358 | 0.60 | MAP3K7 (0.30) | — | |
| SCHEMBL12568355 | 0.60 | MAP3K7 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399500-B2 | Method of synthesizing ergothioneine and analogs | TETRAHEDRON (FR) | 2013-03-19 | — | — | US | disclosed |
| US-20120136159-A1 | THE METHOD OF SYNTHESIZING ERGOTHIONEINE AND ANALOGS | TERTRAHEDRON (FR) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136159-A1 | THE METHOD OF SYNTHESIZING ERGOTHIONEINE AND ANALOGS | TST, SLC6A12, TTPA | SLC22A4 331/4885KDM3B 4522/4885KMT2A 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.